Cartesian Therapeutics Net Income From Continuing Ops Over Time
| RNAC Stock | 6.64 0.11 1.63% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Cartesian Therapeutics Performance and Cartesian Therapeutics Correlation. Cartesian | Build AI portfolio with Cartesian Stock |
Will Biotechnology sector continue expanding? Could Cartesian diversify its offerings? Factors like these will boost the valuation of Cartesian Therapeutics. Anticipated expansion of Cartesian directly elevates investor willingness to pay premium valuations. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Cartesian Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Quarterly Earnings Growth (0.07) | Earnings Share (1.33) | Revenue Per Share | Quarterly Revenue Growth 0.168 | Return On Assets |
The market value of Cartesian Therapeutics is measured differently than its book value, which is the value of Cartesian that is recorded on the company's balance sheet. Investors also form their own opinion of Cartesian Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Cartesian Therapeutics' true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because Cartesian Therapeutics' market value can be influenced by many factors that don't directly affect Cartesian Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between Cartesian Therapeutics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Cartesian Therapeutics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Cartesian Therapeutics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Cross Equities Net Income From Continuing Ops Analysis
Compare Cartesian Therapeutics and related stocks such as Eupraxia Pharmaceuticals, Inventiva Sa, and Nautilus Biotechnology Net Income From Continuing Ops Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EPRX | (3.1 M) | (3.1 M) | (3.1 M) | (3.1 M) | (3.1 M) | (3.1 M) | (3.1 M) | (3.1 M) | (3.1 M) | (3.1 M) | (3.1 M) | (18.3 M) | (19 M) | (29 M) | (25.7 M) | (23.2 M) | (24.3 M) |
| IVA | (7 M) | (7 M) | (7 M) | (7 M) | (7 M) | (7 M) | (7 M) | (17.2 M) | (33.6 M) | (30.2 M) | (33.6 M) | (49.6 M) | (54.3 M) | (110.4 M) | (184.2 M) | (165.8 M) | (157.5 M) |
| NAUT | (15.6 M) | (15.6 M) | (15.6 M) | (15.6 M) | (15.6 M) | (15.6 M) | (15.6 M) | (15.6 M) | (15.6 M) | (15.6 M) | (15.6 M) | (50.3 M) | (57.9 M) | (60.1 M) | (70.8 M) | (63.7 M) | (66.9 M) |
| OBIO | (21.4 M) | (21.4 M) | (21.4 M) | (21.4 M) | (21.4 M) | (21.4 M) | (21.4 M) | (21.4 M) | (21.4 M) | (21.4 M) | (21.4 M) | (23 M) | (33.6 M) | (49.1 M) | (61 M) | (54.9 M) | (57.7 M) |
| MDWD | (8.5 M) | (8.5 M) | (8.5 M) | (8.5 M) | (18.9 M) | (21.7 M) | (18.9 M) | (14.5 M) | (5.7 M) | 2.1 M | (9.3 M) | (13.6 M) | (19.6 M) | (12.4 M) | (30.2 M) | (27.2 M) | (25.8 M) |
| AARD | (13.6 M) | (13.6 M) | (13.6 M) | (13.6 M) | (13.6 M) | (13.6 M) | (13.6 M) | (13.6 M) | (13.6 M) | (13.6 M) | (13.6 M) | (13.6 M) | (13.6 M) | (7.2 M) | (20.6 M) | (18.5 M) | (19.5 M) |
| FENC | 0.0 | 1.8 M | 1.8 M | 1.8 M | (2.2 M) | (659 K) | (2.8 M) | (7 M) | (9.9 M) | (12.8 M) | (18.1 M) | (17.3 M) | (23.7 M) | (20.2 M) | (436 K) | (392.4 K) | (412 K) |
| AVTX | 11.9 M | 11.9 M | 11.9 M | 11.9 M | 11.9 M | 11.9 M | 11.9 M | 11.9 M | (40.1 M) | (16.3 M) | (64.4 M) | (84.3 M) | (41.7 M) | (33.2 M) | (35.1 M) | (31.6 M) | (33.2 M) |
| NTHI | (3.4 M) | (3.4 M) | (3.4 M) | (3.4 M) | (3.4 M) | (3.4 M) | (3.4 M) | (3.4 M) | (3.4 M) | (3.4 M) | (3.4 M) | (3.4 M) | (3 M) | (14.9 M) | (11.9 M) | (10.7 M) | (11.2 M) |
| GNFT | (17.1 M) | (17.1 M) | (17.1 M) | (17.1 M) | (17.1 M) | (17.1 M) | (33.7 M) | (58.6 M) | (79.5 M) | (65.1 M) | (101.2 M) | 67.3 M | (23.7 M) | (28.9 M) | 1.5 M | 1.7 M | 1.8 M |
Cartesian Therapeutics and related stocks such as Eupraxia Pharmaceuticals, Inventiva Sa, and Nautilus Biotechnology Net Income From Continuing Ops description
My Equities
My Current Equities and Potential Positions
| Cartesian Therapeutics | RNAC |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | 7495 New Horizon |
| Exchange | NASDAQ Exchange |
null 6.64
Check out Cartesian Therapeutics Performance and Cartesian Therapeutics Correlation. For information on how to trade Cartesian Stock refer to our How to Trade Cartesian Stock guide.You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.
Cartesian Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.